Literature DB >> 2153479

Abnormal intracellular calcium handling, a major cause of systolic and diastolic dysfunction in ventricular myocardium from patients with heart failure.

J P Morgan1, R E Erny, P D Allen, W Grossman, J K Gwathmey.   

Abstract

Intracellular Ca2+ release and reuptake are necessary for normal contraction and relaxation of the human heart. Intracellular Ca2+ transients were recorded with aequorin during isometric contraction of myocardium from patients with end-stage heart failure. In contrast to controls, contractions and Ca2+ transients of muscles from failing hearts were markedly prolonged, and the Ca2+ transients exhibited two distinct components. Muscles from the failing hearts showed a diminished capacity to restore a low resting Ca2+ level during diastole. These data obtained in actively contracting human myocardium suggest that intracellular Ca2+ handling is abnormal and might cause both systolic and diastolic dysfunction in heart failure. The inotropic effectiveness of drugs that act to increase intracellular levels of cyclic adenosine monophosphate (AMP), such as beta-adrenergic agonists and phosphodiesterase inhibitors, was markedly reduced in muscles from patients with heart failure. In contrast, the effectiveness of inotropic stimulation with drugs that act by cyclic AMP-independent mechanisms, such as the cardiotonic steroids and DPI 201-106, were preserved. Stimulation of intracellular cyclic AMP production by the adenylate cyclase activator forskolin restored the inotropic response to phosphodiesterase inhibitors. These studies indicate that an abnormality in cyclic AMP production may be a fundamental defect in patients with end-stage heart failure that may markedly diminish the effectiveness of agents that depend on generation of this nucleotide for a positive inotropic effect. Moreover, deficient production of cyclic AMP seems, at least in part, to account for the reversal of the force-frequency relation that characterizes failing myocardium. Of interest, direct measurement of total cellular cyclic AMP content and protein kinase activity did not reveal significant differences between the control and myopathic tissue, suggesting the presence in human ventricular muscle of physiologically distinct compartmentalized pools of cyclic AMP. Finally, changes in the sensitivity of the contractile apparatus to Ca2+ also seem to play an important role in the differential responsiveness to drugs of myopathic versus normal human myocardium.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2153479

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  40 in total

1.  Oxidative stress in the aging rat heart is reversed by dietary supplementation with (R)-(alpha)-lipoic acid.

Authors:  J H Suh; E T Shigeno; J D Morrow; B Cox; A E Rocha; B Frei; T M Hagen
Journal:  FASEB J       Date:  2001-03       Impact factor: 5.191

2.  Effects of increased preload on the force-frequency response and contractile kinetics in early stages of cardiac muscle hypertrophy.

Authors:  Kaylan M Haizlip; Tepmanas Bupha-Intr; Brandon J Biesiadecki; Paul M L Janssen
Journal:  Am J Physiol Heart Circ Physiol       Date:  2012-03-30       Impact factor: 4.733

Review 3.  Myocardial contraction-relaxation coupling.

Authors:  Paul M L Janssen
Journal:  Am J Physiol Heart Circ Physiol       Date:  2010-09-17       Impact factor: 4.733

4.  Systolic-diastolic coupling of myocardial deformation of the left ventricle in children with left ventricular noncompaction.

Authors:  C Koh; W J Hong; S J Wong; Y F Cheung
Journal:  Heart Vessels       Date:  2010-09-28       Impact factor: 2.037

Review 5.  Cardiac gene therapy with SERCA2a: from bench to bedside.

Authors:  Judith K Gwathmey; Alexan I Yerevanian; Roger J Hajjar
Journal:  J Mol Cell Cardiol       Date:  2010-11-18       Impact factor: 5.000

Review 6.  Mechanisms of altered Ca²⁺ handling in heart failure.

Authors:  Min Luo; Mark E Anderson
Journal:  Circ Res       Date:  2013-08-30       Impact factor: 17.367

7.  S100A1 DNA-based Inotropic Therapy Protects Against Proarrhythmogenic Ryanodine Receptor 2 Dysfunction.

Authors:  Julia Ritterhoff; Mirko Völkers; Andreas Seitz; Kristin Spaich; Erhe Gao; Karsten Peppel; Sven T Pleger; Wolfram H Zimmermann; Oliver Friedrich; Rainer H A Fink; Walter J Koch; Hugo A Katus; Patrick Most
Journal:  Mol Ther       Date:  2015-05-25       Impact factor: 11.454

8.  Evaluation of the regional responsivity to ryanodine of human myocardium from patients with idiopathic dilated cardiomyopathy and secondary cardiomyopathies.

Authors:  R Padrini; M Panfili; L Testolin; F Pesarin; D Piovan; G Magnolfi; U Livi; D Casarotto; S Dalla Volta
Journal:  Basic Res Cardiol       Date:  1996 Sep-Oct       Impact factor: 17.165

9.  Endocardial endothelium is a key determinant of force-frequency relationship in rat ventricular myocardium.

Authors:  Xiaoxu Shen; Zhen Tan; Xin Zhong; Ye Tian; Xian Wang; Bo Yu; Genaro Ramirez-Correa; Anne Murphy; Kathleen Gabrielson; Nazareno Paolocci; Wei Dong Gao
Journal:  J Appl Physiol (1985)       Date:  2013-05-23

10.  Partial prevention of changes in SR gene expression in congestive heart failure due to myocardial infarction by enalapril or losartan.

Authors:  Xiaobing Guo; Donald Chapman; Naranjan S Dhalla
Journal:  Mol Cell Biochem       Date:  2003-12       Impact factor: 3.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.